**Technology Development Fund**

**Advisory Board**

|  |  |
| --- | --- |
| Advisory Board Member | Title and Organization |
| Joe Bolen, PhD | Chief Scientific Officer at PureTech Health |
| Jerry Casey, MBA | Independent Consultant  Former President and COO, Sekisui Diagnostics, LLC |
| Margaret Chu-Moyer, PhD | Executive Director of Research, and Massachusetts Site Head, Amgen |
| Anthony J. Coyle, PhD | CEO at Pandion Therapeutics |
| Alan Crane, MBA | Venture Partner and Entrepreneur, Polaris Venture Partners |
| Skip Fleshman, MS | Partner, Asset Management Ventures |
| Sandra Glucksman, PhD | Entrepreneur In Residence at Third Rock Ventures |
| Keith Gottesdiener, MD | CEO, Rhythm Pharmaceuticals, Inc. |
| Michael Magliochetti, MBA, PhD | Operating Partner, Riverside Partners |
| Patrice Milos, PhD | President, CEO and Founder, Medley Genomics |
| Imran Nasrullah, MS, JD, CLP | Director, Innovation Sourcing, Boehringer Ingelheim |
| Simon Read, PhD | Chief Scientific Officer, Ra Pharma |
| Ken Rhodes, PhD | Chief Scientific Officer, Yumanity Therapeutics |
| Craig Sorensen, PhD | Independent Pharma Consultant  Former Vice President, External Research and Innovation, Vertex Pharmaceuticals Inc. |
| Beverly Teicher, PhD | Chief, Molecular Pharmacology Branch, National Cancer Institute |
| Josh Tolkoff, MS Eng | Managing Director, Ironwood Capital Management; Accelerator Executive, CIMIT |
| Stacie Weninger, PhD | Executive Director, F-Prime Biomedical Research Initiative |